Gene editing holds promise for treating many conditions, but the bacterial origins of RNA-editing enzymes has been found to activate unwanted immune responses in healthy people.
Experimental gene therapy promises a new lease of life for patients with genetic heart disease.
Nuevocor, an A*STAR spin-off company, is designing novel therapies to target the genetic causes of heart diseases, bringing basic research to clinical impact.
Uncovering the molecular mechanisms behind immune system activation could help in future gene therapies
New design guidelines from researchers in Singapore simplify the development of targeted therapies for muscular dystrophy and other diseases
Through a combination of two powerful methodologies, researchers at the A*STAR Institute of Bioengineering and Nanotechnology drive forward promising developments for gene therapy
Adding back a gene that is missing in cells from patients with skin fragility disorders restores the cells’ normal response to stress
Gene therapy restores adaptive immunity in patients with chronic hepatitis B and directs T cells to tumor cells in patients with hepatitis B virus-related hepatocellular carcinoma